Growth Metrics

Bristol Myers Squibb (BMYMP) Cash & Current Investments (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Cash & Current Investments for 17 consecutive years, with $10.7 billion as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments fell 1.71% to $10.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.7 billion through Dec 2025, down 1.71% year-over-year, with the annual reading at $10.7 billion for FY2025, 1.71% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $10.7 billion at Bristol Myers Squibb, down from $16.5 billion in the prior quarter.
  • The five-year high for Cash & Current Investments was $17.0 billion in Q4 2021, with the low at $6.7 billion in Q2 2024.
  • Average Cash & Current Investments over 5 years is $11.5 billion, with a median of $11.3 billion recorded in 2024.
  • The sharpest move saw Cash & Current Investments plummeted 45.46% in 2022, then soared 104.46% in 2025.
  • Over 5 years, Cash & Current Investments stood at $17.0 billion in 2021, then tumbled by 45.46% to $9.3 billion in 2022, then skyrocketed by 32.71% to $12.3 billion in 2023, then decreased by 11.57% to $10.9 billion in 2024, then dropped by 1.71% to $10.7 billion in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $10.7 billion, $16.5 billion, and $13.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.